Mesenchymal stem/stromal cells in the pathogenesis and regenerative therapy of inflammatory bowel diseases

Che, Zhengping; Ye, Ziyu; Zhang, Xueying; Lin, Bihua; Yang, Weiqing; Liang, Yuanxin; Zeng, Jincheng

doi:10.3389/fimmu.2022.952071

Cited by 16 publications

(14 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, MSC transplantation has been considered a novel therapeutic approach for IBD with the potential to regulate the immune response and promote tissue regeneration [23]. In addition to the frequently used UcMSCs, MenSCs have attracted notable attention as a promising alternative stem cell based therapy for various diseases based on their wide-ranging advantages, such as their regular and noninvasive collection method, abundant availability, superior proliferative capacity and autologous transplantation potential [24].…”

Section: Discussionmentioning

confidence: 99%

MenSCs ameliorate experimental colitis by protecting intestinal barrier integrity by inhibiting the NF-κB/Snail signaling pathway

Ruan,

Xue,

Han

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC) are chronic recurrent nonspecific intestinal disease that are characterized by intestinal epithelial barrier dysfunction and excessive activation of the mucosal immune system. In this study, we aimed to investigate the effects and mechanisms of menstrual blood-derived stem cells(MenSCs) against colon inflammation and mucosal tissue repair. Methods: LPS-exposed human colonic epithelial cancer cell line Caco2, and HT29. Tight junction(TJ) proteins and the level of inflammatory factors were assessed by Western blot and qRT-PCR. MenSCswere co-cultured with LPS-exposed human colonic epithelial cancer cell line, HT29, dextran sulfate sodium (DSS)-induced IBD mouse models were intravenously administered MenSCs. Effects of MenSCs on intestinal inflammation, and colon barrier function were investigated. Finally, NF-κB-snail signaling pathway were assessed by western blot. Results: LPS downregulates intercellular junction proteins, and induces the production of inflammatory cytokines in intestinal epithelial cells. MenSCs mitigated DSS-induced colitis in mice, by reducing body weight loss, colonic shortening, and disease activity index scores and by inhibiting the expressions of the proinflammatory cytokines IL-1β, IL-6, and TNF-α. MenSCs increased the expression of TJ proteins, improved the destruction of tight junction (TJ) structures and reduced intestinal epithelial permeability. Furthermore, MenSCs could inhibit NF-κB p65 phosphorylation and the expression of Snail and prevent Snail nuclear localization, thereby maintaining tight and adherens junctions. Conclusions: Our data demonstrate that MenSCsalleviates gut inflammation, protects intestinal mucosal barrier by inhibiting the NF-κB /Snail signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

MenSCs ameliorate experimental colitis by protecting intestinal barrier integrity by inhibiting the NF-κB/Snail signaling pathway

Ruan,

Xue,

Han

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Short bowel syndrome (SBS) is the most apparent indication affecting the small intestine [87]. Tissue engineering can also be a therapeutic option for diseases which need the removal of a substantial part of the intestines, such as inflammatory bowel diseases [88], including Crohn's disease and Ulcerative Colitis, but also cancers. SBS corresponds to an inadequate functional intestinal epithelium or its drastic reduction in surface following surgical resection.…”

Section: The Intestinesmentioning

confidence: 99%

Tissue Engineering for Gastrointestinal and Genitourinary Tracts

Elia¹,

Brownell²,

Chabaud³

et al. 2022

Preprint

View full text Add to dashboard Cite

The gastrointestinal and genitourinary tracts share several similarities. Primarily, these tissues are composed of hollow structures lined by an epithelium through which materials need to flow with the help of peristalsis brought by muscle contraction. In the case of the gastrointestinal tract, solid or liquid food must circulate to be digested and absorbed and the waste products eliminated. In the case of the urinary tract, the urine produced by the kidneys must flow to the bladder, where it is stored until its elimination from the body. Finally, in the case of the vagina, it must allow the evacuation of blood during menstruation, accommodate the male sexual organ during coitus, and is the natural way to birth a child. The present review describes the anatomy, pathologies and treatments of such organs, emphasizing tissue engineering strategies.

show abstract

“… 14 , 15 Transplantation of SCs can regulate or rebuild immune cells, repair or supplement structural cells, such as intestinal epithelial cells (IECs), and potentially lead to a complete cure of IBD. 16 , 17 This review summarizes recent research on the use of SCs for treating IBD, providing targeted treatment recommendations and research strategies for IBD patients.…”

Section: Introductionmentioning

confidence: 99%

Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges

Tian¹,

Zhang²,

Yang³

et al. 2023

JIR

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a group of chronic inflammatory diseases of the gastrointestinal tract. Repeated inflammation can lead to complications, such as intestinal fistula, obstruction, perforation, and bleeding. Unfortunately, achieving durable remission and mucosal healing (MH) with current treatments is difficult. Stem cells (SCs) have the potential to modulate immunity, suppress inflammation, and have anti-apoptotic and pro-angiogenic effects, making them an ideal therapeutic strategy to target chronic inflammation and intestinal damage in IBD. In recent years, hematopoietic stem cells (HSCs) and adult mesenchymal stem cells (MSCs) have shown efficacy in treating IBD. In addition, numerous clinical trials have evaluated the efficiency of MSCs in treating the disease. This review summarizes the current research progress on the safety and efficacy of SC-based therapy for IBD in both preclinical models and clinical trials. We discuss potential mechanisms of SC therapy, including tissue repair, paracrine effects, and the promotion of angiogenesis, immune regulation, and anti-inflammatory effects. We also summarize current SC engineering strategies aimed at enhancing the immunosuppressive and regenerative capabilities of SCs for treating intestinal diseases. Additionally, we highlight current limitations and future perspectives of SC-related therapy for IBD.

show abstract

Mesenchymal stem/stromal cells in the pathogenesis and regenerative therapy of inflammatory bowel diseases

Cited by 16 publications

References 153 publications

MenSCs ameliorate experimental colitis by protecting intestinal barrier integrity by inhibiting the NF-κB/Snail signaling pathway

MenSCs ameliorate experimental colitis by protecting intestinal barrier integrity by inhibiting the NF-κB/Snail signaling pathway

Tissue Engineering for Gastrointestinal and Genitourinary Tracts

Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges

Contact Info

Product

Resources

About